Pharmaceuticals company Breckenridge Pharmaceutical Inc reported on Friday the receipt of approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Pomalidomide Capsules.
The company has partnered with Natco Pharma Limited for the development and manufacture of Pomalidomide Capsules (generic, Pomalyst). Pomalidomide is an anti-angiogenic and also acts as an immunomodulator.
Based on the industry sales data, Pomalyst had annual sales of USD957m during the 12 months ending September 2020.
In conjunction, Celgene, Breckenridge and Natco have settled the US district court litigation with respect to Pomalyst.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US